Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-816-6640
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.32 million
Profitability
Miscellaneous
Employees88
OptionableOptionable
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics PLC - (NASDAQ:NBRV) released its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.04. The biotechnology company had revenue of $0.85 million for the quarter, compared to the consensus estimate of $1.16 million. Nabriva Therapeutics had a negative return on equity of 87.03% and a negative net margin of 1,064.19%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
8 analysts have issued twelve-month price targets for Nabriva Therapeutics' shares. Their predictions range from $5.00 to $18.00. On average, they expect Nabriva Therapeutics' stock price to reach $11.1667 in the next year. This suggests a possible upside of 442.1% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.
What is the consensus analysts' recommendation for Nabriva Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.
Has Nabriva Therapeutics been receiving favorable news coverage?
News stories about NBRV stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.
Are investors shorting Nabriva Therapeutics?
Nabriva Therapeutics saw a decline in short interest in January. As of January 31st, there was short interest totalling 297,238 shares, a decline of 62.0% from the January 15th total of 782,642 shares. Based on an average trading volume of 302,378 shares, the short-interest ratio is presently 1.0 days. Currently, 0.7% of the company's stock are sold short. View Nabriva Therapeutics' Current Options Chain.
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN), Alkermes (ALKS), FibroGen (FGEN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS) and Intercept Pharmaceuticals (ICPT).
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Mr. Steven P. Gelone, Pres & COO (Age 51)
- Dr. Colin Broom, Consultant & Director (Age 63)
- Mr. Gary L. Sender, Chief Financial Officer (Age 57)
- Mr. Theodore R. Schroeder, CEO & Director (Age 64)
- Mr. Thomas Lembck, Chief Information Officer
Who are Nabriva Therapeutics' major shareholders?
Nabriva Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Frazier Management LLC (0.60%), Aisling Capital Management LP (0.27%), United Services Automobile Association (0.05%), Bank of America Corp DE (0.02%), Wedbush Securities Inc. (0.02%) and Clear Harbor Asset Management LLC (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.
Which major investors are selling Nabriva Therapeutics stock?
NBRV stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Clear Harbor Asset Management LLC, Two Sigma Investments LP, Bank of America Corp DE and United Services Automobile Association. View Insider Buying and Selling for Nabriva Therapeutics.
Which major investors are buying Nabriva Therapeutics stock?
NBRV stock was acquired by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Paloma Partners Management Co, Two Sigma Advisers LP, HRT Financial LLC, Jane Street Group LLC and Wedbush Securities Inc.. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $2.06.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $1.38 billion and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.
What is Nabriva Therapeutics' official website?
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
